Breaking Finance News

Barclays PLC downgraded Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to Equal Weight in a statement released earlier today.

Barclays PLC has downgraded Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to Equal Weight in a statement released on 05/22/2017.

On Wednesday March 08, 2017, Zacks Investment Research released a statement on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) upped the target price from $0.00 to $16.00 that suggested an upside of 0.12%.

Having a price of $15.55, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded -13.71% lower on the day. With the last close down -4.50% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.01% over the same period. MNTA has recorded a 50-day average of $16.83 and a two hundred day average of $15.81. Trade Volume was up over the average, with 5,150,892 shares of MNTA changing hands over the typical 632,197

Recent Performance Chart

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

Momenta Pharmaceuticals, Inc. has with a one year low of $10.75 and a one year high of $19.90 and has a market capitalization of $0.

A total of 9 analysts have released a report on Momenta Pharmaceuticals, Inc.. Five analysts rating the company a strong buy, one analyst rating the company a buy, three analysts rating the company a hold, one analyst rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $16.33.

General Company Details For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *